Navigation Links
ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
Date:6/27/2011

al programs in advanced preclinical development.  ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.

Certain statements in this press release may constitute "forward-looking statements". These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy or actual results to differ materially from those expressed or implied. We do not intend, and undertake no obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
2. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
4. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
5. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
6. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
7. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
8. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
9. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
10. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
11. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... N.C. , March 31, 2015 PGI ... capabilities in North America at ... facility. The anticipated plant expansion is centered ... a need for differentiated products for personal care product ... state-of-the-art printing capabilities with in-line slitting and packaging, will ...
(Date:3/31/2015)... Israel, March 31, 2015  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of ... liver diseases and cholesterol gallstones, today announced financial ... 2014. Fourth Quarter 2014 Highlights: ... a keynote address by Professor Rohit Loomba, MD, ...
(Date:3/31/2015)... , Mar. 27, 2015 Research and Markets ... addition of the "European Laboratory Information System ... by Type (Clinical Pathology Laboratory Information System, Anatomic ... report to their offering. The ... grow at a CAGR of 7.6% from 2014 ...
Breaking Medicine Technology:PGI Expands Manufacturing Capabilities At Mexico Plant 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 2European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 3
... Vista Partners announced today that it has updated coverage ... PRWP ) ("the Company") and maintains its twelve month target ... stated, "DAVANAT®, the Company,s lead product candidate, could potentially enhance ... Avastin® , while also reducing the side effect profile of ...
... Tenn. and MERCER ISLAND, Wash., Dec. 22, 2010 Renal ... to form the third largest provider of dialysis services in ...  The transaction – terms of which were not disclosed – ... 5,300 employees serving more than 19,000 patients in 260 locations ...
Cached Medicine Technology:Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10 2Renal Advantage and Liberty Dialysis Deal Completed 2Renal Advantage and Liberty Dialysis Deal Completed 3
(Date:3/31/2015)... Stem cells may provide Crohn’s disease ... – fistulas – according to the results of a ... of STEM CELLS Translational Medicine (SCTM). After receiving an ... are collected from fat tissue, the fistulas in 75 ... eight weeks of their last treatment and remained so ...
(Date:3/31/2015)... 31, 2015 Diane Blackburn-Zambetti is ... the Mesothelioma Applied Research Foundation (Meso Foundation). Blackburn-Zambetti ... Your Health” at the BoRit Asbestos Superfund Citizen ... This program will discuss anatomy, six types of ... diseases, symptoms, treatments, prevention and proper communication with ...
(Date:3/31/2015)... PharmMD CEO Robert Yeager ... newly created, senior executive role of Chief Technology Officer ... delivery of high quality, efficient, reliable, and secure applications, ... momentum as a market innovator for Part D Star ... “We were very strategic in our search for the ...
(Date:3/31/2015)... Mega Photo, from the makers of Slidezilla, have created ... free app brings a new found life to photos and ... masterpieces. Mega Photo provides over a 100 effects for users ... images in 3-D. , Founder Paul Falstad said that ... it has real-time view so users can try out any ...
(Date:3/31/2015)... St. Louis, MO (PRWEB) March 31, 2015 ... April 8, 2015 from 5:00 to 8:00 pm at the ... than 50 hospitals, clinics and groups with career opportunities will ... represented. Attendees will enjoy free hors d’oeuvres and raffle prize ... PracticeMatch says “Denver is an ideal location to hold ...
Breaking Medicine News(10 mins):Health News:Trial Shows Stem Cells Provide Long-Term Relief from Dangerous Crohn’s Side Effect 2Health News:Mesothelioma Foundation to speak at BoRit Asbestos Superfund Citizen Advisory Group Meeting 2Health News:PharmMD Places Victor Mattingly in C-Suite, Company Focused on Medication Therapy Management and Part D Star Ratings 2Health News:New Mega Photo App Launched and Provides the Ultimate Playground for Photos 2Health News:PracticeMatch to Host Physician Career Fair at SpringHill Suites Denver on April 8, 2015 2Health News:PracticeMatch to Host Physician Career Fair at SpringHill Suites Denver on April 8, 2015 3
... ... ... , ... , , , ...
... workshop have been released to address deep-vein thrombosis (DVT) ... estimated to affect nearly 1 million Americans each year. ... representatives from federal health agencies and patient groups, as ... communities appear in the March 9, 2010, ...
... a successful relationship partners shouldn,t go to bed angry. ... that brain activityspecifically in the region called the lateral prefrontal ... in the days following a fight with his or her ... lateral prefrontal cortex are less likely to be upset the ...
... oophorectomy) while performing a hysterectomy is common practice to ... procedure is performed in 55 percent of all US ... year. An article in the March/April issue of t ... ovaries (bilateral oophorectomy) while performing a hysterectomy is common ...
... anxiety, depression and stress lessened, researchers say , TUESDAY, March ... psychological woes in patients with lupus who have high levels ... also helps these patients improve and maintain their quality of ... included 45 patients randomly assigned to a control group or ...
... ... only seven one-hundredths of one percent of the products manufactured by the company. , ... Dinuba, CA (Vocus) March 9, 2010 ... potential salmonella exposure. To date, no salmonella-related illnesses have been reported in conjunction to ...
Cached Medicine News:Health News:South Dakota Students with Asthma Can Breathe Easier After New Law Allows Self-Administered Medications 2Health News:Critical recommendations unveiled: Deep-vein thrombosis and pulmonary embolism 2Health News:Critical recommendations unveiled: Deep-vein thrombosis and pulmonary embolism 3Health News:After a fight with a partner, brain activity predicts emotional resiliency 2Health News:New study questions benefits of elective removal of ovaries during hysterectomy 2
PremierEdge™ Stab Knives - 45°....
PremierEdge™ Stab Knives - 30°....
PremierEdge™ Stab Knives - 22.5°....
Lacrimal Intubation Set w/Retrieval Device. Size: Probes 23g x 4-1/4"....
Medicine Products: